Medication Management, Oncology
Cancer-associated Thrombosis. Up to date knowledge for GP’s on diagnosing and treating DVT in patients with cancer.
Venous thromboembolism (VTE) is a common and life-threatening complication in patients with cancer. The incidence of cancer-associated VTE varies depending on cancer type, disease stage, time since diagnosis and treatment status. Management can be challenging because these patients are often also at increased bleeding risk.
Clinical trials have found that the direct oral anticoagulants (DOACs) rivaroxaban and apixaban have comparable efficacy and safety to low molecular weight heparin (LMWH) in treating VTE in patients with cancer.
Current clinical guidelines recommend considering a DOAC both for initial treatment and for short- and long-term treatment of people with active cancer and confirmed proximal DVT or PE.
This program will help improve your skills and knowledge when diagnosing and treating DVT in patients with cancer.
DURATION
30 min
PROFESSION
Physician, Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-09-26
Venous thromboembolism (VTE) is a common and life-threatening complication in patients with cancer. The incidence of cancer-associated VTE varies depending on cancer type, disease stage, time since diagnosis and treatment status. Management can be challenging because these patients are often also at increased bleeding risk.
Clinical trials have found that the direct oral anticoagulants (DOACs) rivaroxaban and apixaban have comparable efficacy and safety to low molecular weight heparin (LMWH) in treating VTE in patients with cancer.
Current clinical guidelines recommend considering a DOAC both for initial treatment and for short- and long-term treatment of people with active cancer and confirmed proximal DVT or PE.
This program will help improve your skills and knowledge when diagnosing and treating DVT in patients with cancer.
Also watch Expert Panel Discussion Cancer-associated Thrombosis “What GP’s need to know”.
This educational activity was developed by MDBriefCase at the request, and with funding from BMS & Pfizer Alliance.
Faculty
Damian Flanagan, GP, Mornington Peninsula, Victoria
Amanda Hugman, Haematologist, MBBS FRACP FRCPA MPhil
Jia (Jenny) Liu, Medical Oncologist, BMed(Hons) BMedSci(Hons) MD PhD FRACP
Learning objectives
Upon completion of this program, clinicians will be better able to::
- Appreciate the prevalence and burden of venous thromboembolic disease in patients with cancer
- Identify risk factors associated with cancer-associated venous thromboembolism and intervene early to avoid unnecessary morbidity
- Understand the recent data and guideline recommendations on the use of direct oral anticoagulants (DOACs) to treat cancer-associated venous thromboembolism
- Understand the GP’s role in venous thromboembolism management
Accreditation
This 30-minute interactive online learning activity is accredited by the Royal Australian College of General Practitioners for 1 point.
Members are able to claim CPD activity points for 1 point through 'Quick log' on their RACGP CPD Dashboard.
# of credits: 0
Duration: 30 min
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
